Ovarian cancer is one of the major causes of death for women in the United States. Overexpression of the HER-2/neu oncogene has been reported to correlate with poor prognosis for ovarian cancer patients. Therefore, HER-2/neu may be an excellent target for novel anti-cancer agents, particularl those cancers with overexpression of HER-2/neu. The applicant's experimental results indicate that PEA3, a transcriptional factor from the ETS family, represses HER-2/neu transcription in HER-2/neu-overexpressing cancer cells, an that PEA3-liposome complexes may inhibit tumor growth in an animal model of ovarian cancer. The applicant has hypothesized, therefore, that PEA3, through repression of HER-2/neu, may function as a tumor suppressor for HER-2/neu-overexpressing ovarian cancer cells. The long-term goal of the proposed work is to understand the molecular mechanisms by which PEA3 suppresses tumor growth and to develop novel approaches to the treatment of HER-2/neu-overexpressing ovarian cancer cells. The following five specific aim are proposed: 1) to confirm that PEA3 mediates tumor suppression and to determine whether it mediates repression as a result of inhibiting HER-2/neu expression. 2) To investigate the mechanisms and sequences necessary for PEA3 inhibition of HER-2/neu. 3) To examine the preclinical therapeutic effects of PEA3. 4) To test potential synergistic effects of PEA3 gene therapy and chemotherapy for ovarian cancer cells with HER-2/neu overexpression. 5) To design expression vectors for preferential expression of PEA3 in HER-2/neu-overexpressing ovarian cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA077858-03
Application #
6173655
Study Section
Special Emphasis Panel (ZRG2-MEP (01))
Program Officer
Wolpert, Mary K
Project Start
1998-04-01
Project End
2002-03-31
Budget Start
2000-04-01
Budget End
2002-03-31
Support Year
3
Fiscal Year
2000
Total Cost
$225,130
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Biology
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Xia, Wei-Ya; Lien, Huang-Chun; Wang, Shao-Chun et al. (2006) Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer. Breast Cancer Res Treat 98:295-301
Yu, Zhenming; Xia, Weiya; Wang, Hong-Ying et al. (2006) Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. Mol Carcinog 45:667-75
Yan, Duen-Hwa; Wen, Yong; Su, Li-Kuo et al. (2004) A delayed chemically induced tumorigenesis in Brca2 mutant mice. Oncogene 23:1896-901
Zhou, Binhua P; Hung, Mien-Chie (2002) Novel targets of Akt, p21(Cipl/WAF1), and MDM2. Semin Oncol 29:62-70
Lee, Wei-Ping; Wen, Yong; Varnum, Brian et al. (2002) Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 21:329-36
Ding, Yi; Wen, Yong; Spohn, Bill et al. (2002) Proapoptotic and antitumor activities of adenovirus-mediated p202 gene transfer. Clin Cancer Res 8:3290-7
Ueno, Naoto T; Bartholomeusz, Chandra; Xia, Weiya et al. (2002) Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 62:6712-6
Deng, Jiong; Zhang, Haifan; Kloosterboer, Freke et al. (2002) Ceramide does not act as a general second messenger for ultraviolet-induced apoptosis. Oncogene 21:44-52
Wang, Shao-Chun; Shao, Ruping; Pao, Annie Y et al. (2002) Inhibition of cancer cell growth by BRCA2. Cancer Res 62:1311-4
Deng, Jiong; Kloosterbooer, Freke; Xia, Weiya et al. (2002) The NH(2)-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression. Cancer Res 62:346-50

Showing the most recent 10 out of 24 publications